Compare NCNO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | VCEL |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2022 | 1996 |
| Metric | NCNO | VCEL |
|---|---|---|
| Price | $23.63 | $40.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $26.07 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.5M | 446.8K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.15 | 60.00 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $594,781,000.00 | $276,259,000.00 |
| Revenue This Year | $9.53 | $19.40 |
| Revenue Next Year | $8.97 | $18.24 |
| P/E Ratio | $127.56 | ★ N/A |
| Revenue Growth | 10.01 | ★ 16.45 |
| 52 Week Low | $13.80 | $28.95 |
| 52 Week High | $31.23 | $49.32 |
| Indicator | NCNO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 72.58 | 36.97 |
| Support Level | $22.81 | $35.45 |
| Resistance Level | $26.21 | $42.16 |
| Average True Range (ATR) | 0.95 | 1.42 |
| MACD | 0.15 | -0.28 |
| Stochastic Oscillator | 89.30 | 17.69 |
Ncino Inc is a provider of cloud-based software for financial institutions. It is focused on developing the nCino Platform to transform commercial and small business lending for community and regional banks in the U.S. With the company's platform financial institutions can Operate More Intelligently, Improve Efficiency, Elevate Employee and Client Experiences, and Manage Risk and Compliance Continuously Rather Than Reactively. It has built and acquired technology, including SimpleNexus, DocFox, FullCircl, ILT, Visible Equity, FinSuite, and Sandbox Banking, to augment the nCino Platform's capabilities for mortgage lending, onboarding, account opening, indirect auto lending, and analytics and AI. The company operates as one operating segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.